For a post‑CABG patient, what other medications is he currently taking and what are the potential interactions or precautions when initiating modafinil?

Standard Post-CABG Medications and Modafinil Considerations

Your post-CABG patient should be on aspirin (100-325 mg daily), a statin, and likely a beta-blocker and/or ACE inhibitor—modafinil can be used cautiously but requires awareness of drug interactions, particularly with CYP3A4 substrates and CYP2C19 inhibition.

Core Post-CABG Medication Regimen

Based on ACC/AHA guidelines, your patient is almost certainly taking 1:

Mandatory Medications (Class I)

• Aspirin 100-325 mg daily - Should have been initiated within 6 hours post-operatively and continued indefinitely for graft patency
• Statin therapy - All post-CABG patients require statins unless contraindicated, targeting LDL <100 mg/dL (or <70 mg/dL in very high-risk patients)

Likely Additional Medications (Class IIa)

• Clopidogrel 75 mg daily - If aspirin-intolerant, or if patient had recent PCI with stenting (dual antiplatelet therapy for 9-12 months) 2
• Beta-blockers - Commonly prescribed post-CABG, though recent evidence questions routine use 3
• ACE inhibitors or ARBs - Particularly if patient has heart failure, diabetes, or reduced ejection fraction 3

Critical Modafinil Drug Interactions

CYP3A4 Induction (Major Concern)

Modafinil is a weak-to-moderate CYP3A4 inducer that becomes clinically significant at steady state (after 7 days of dosing) 4, 5:

• Statins metabolized by CYP3A4 (atorvastatin, simvastatin, lovastatin) may have reduced efficacy

  • Consider switching to rosuvastatin or pravastatin (non-CYP3A4 substrates) or monitoring lipid levels more closely
  • At steady state, modafinil reduced midazolam AUC by 34% 5, suggesting meaningful CYP3A4 induction

• Clopidogrel - If patient is on this antiplatelet, modafinil's CYP3A4 induction could theoretically increase active metabolite formation, but clinical significance is unclear

CYP2C19 Inhibition (Moderate Concern)

Modafinil reversibly inhibits CYP2C19 4, 6:

• Omeprazole or other PPIs (commonly prescribed post-CABG for GI protection with aspirin) - Modafinil increased omeprazole AUC by 36% after single dose and 90% at steady state 5
• Clopidogrel - CYP2C19 inhibition could reduce conversion to active metabolite, potentially decreasing antiplatelet efficacy (though clopidogrel is primarily activated by CYP2C19, not inhibited)

Cardiovascular Safety Concerns

• Arrhythmia risk: Case reports document modafinil-induced ventricular tachycardia even in healthy individuals 7
• Blood pressure effects: Monitor BP as modafinil can cause modest increases
• Post-stroke patients showed rare hyperkinetic movements 8, suggesting CNS vulnerability in cardiovascular patients

Practical Management Algorithm

Before Starting Modafinil:

1. Verify current medication list, specifically:

   • Which statin (switch from atorvastatin/simvastatin to rosuvastatin/pravastatin if possible)
   • Whether on clopidogrel (consider monitoring platelet function or switching to ticagrelor if dual antiplatelet therapy needed)
   • PPI use (may need dose adjustment or monitoring)

2. Baseline assessment:

   • Recent lipid panel
   • ECG to rule out baseline arrhythmias
   • Blood pressure

3. Start low: 100 mg daily (not 200 mg) given elderly patients may have reduced clearance 4

Monitoring After Initiation:

• Week 1-2: Check for palpitations, chest pain, or new arrhythmias
• Week 4: Repeat lipid panel if on CYP3A4-metabolized statin
• Ongoing: Monitor for signs of reduced antiplatelet efficacy if on clopidogrel (recurrent angina, ischemic symptoms)

Key Caveats

The evidence for modafinil in post-CABG patients is completely absent—all interaction data comes from healthy volunteers or other populations. The combination of:

• Potential CYP3A4 induction reducing statin efficacy
• CYP2C19 inhibition affecting clopidogrel activation
• Rare but documented arrhythmogenic potential
• Elderly patients with reduced drug clearance

...makes this a higher-risk scenario than typical modafinil use. Consider whether the indication (likely fatigue or sleepiness) justifies these risks, or if alternative approaches (cardiac rehabilitation, depression screening 9, sleep study for OSA) might be safer first-line options.

If proceeding, document the risk-benefit discussion and maintain closer monitoring than you would in a healthy patient.